- cafead   Nov 21, 2022 at 10:22: AM
via The FDA has a number of PDUFA dates for the remainder of November for Spectrum's poziotinib in NSCLC, ImmunoGen's mirvetuximab soravtansine in ovarian cancer, Scynexis' Brexafemme in RVVC and more.
article source
article source